Typhoon Trauma: The Pharma Score on Disaster Relief
Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan ...Read more |
Doubts Over Data Disclosure in Europe
The European Medicines Agency’s ambitions are huge, but its capacities to achieve what it sets out to do are now falling ever shorter. The latest deficiency is revealed by its admission that it cannot meet its own time-line on disclosure of clinical trial data. Reflector reports ... Read more
|
Pharma Needs to Do More Than Attract Digital Talent
As digital becomes a greater part of the pharma marketing mainstream, can the sector attract the digital marketing talent it needs to succeed in the space? Peter Houston reports ... Read more
|
Can Big Pharma Solve Its Cost Problems by Going Virtual?
Not entirely, writes Ben Comer, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals ... Read more
|
No More Mr NICE Guy: Big Pharma Takes on UK Drug Watchdog
Last week, nine of the world’s largest pharma companies wrote an open letter to accuse the UK’s drug spend watchdog NICE of blocking too many innovative medicines. NICE responded with some soothing words, but is that enough? ... Read more
|
Pharm Exec Global Digest — Real World Evidence Special
Why Real World Evidence is here to stay — and what you need to do to integrate it into your business strategy as painlessly as possible ... Read more
|
|
|
PHT Corporation |
 How to Implement an ePRO Strategy; A FREE Best Practices Guide. Four pharma patient reported outcome (PRO) experts explain how to implement and leverage the efficiencies of an ePRO strategy.  Read the complimentary eBook here. |
|
|
|
|
|
| Sciformix |
 Product labeling– Increasing efficiency, enhancing quality, and delivering compliance
Pharmaceutical product labeling is a highly regulated and complex process. A product label is very specific in its content, with respect to safety data, adverse effects and compliance to country specific regulations.  Read more. |
|
|
|
|
|
|
